Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis.

ABSTRACT:

Objective

Cases of inflammatory bowel disease (IBD) during treatment with interleukin (IL)-17 antagonists have been reported from trials in psoriasis, psoriatic arthritis, and ankylosing spondylitis. The aim of this study was to assess the overall risk for development of IBD due to IL-17 inhibition.

Design

Systematic review and meta-analysis of studies conducted 2010-2018 of treatment with IL-17 antagonists in patients with psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis. We compared risk of IBD development in anti-IL-17 treated patients compared to placebo treatments. We also computed incident rates of IBD overall. A 'worst case scenario' defining subjects ambiguous for prevalent versus incident cases for the latter was also applied.

Resu

SUBMITTER: Burisch J 

PROVIDER: S-EPMC7252630 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature